154 related articles for article (PubMed ID: 9831966)
1. Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease.
Tanaka E
J Clin Pharm Ther; 1998 Jun; 23(3):161-70. PubMed ID: 9831966
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450: genetic polymorphism and drug interactions.
Belpaire FM; Bogaert MG
Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
[TBL] [Abstract][Full Text] [Related]
4. Identification of the human liver cytochrome P450 isoenzymes responsible for the 5-methylhydroxylation of the novel anti-fibrotic drug AKF-PD.
He X; Luo X; Liu Z; Hu G; Cheng Z
Xenobiotica; 2011 Oct; 41(10):844-50. PubMed ID: 21679010
[TBL] [Abstract][Full Text] [Related]
5. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.
Puozzo C; Lens S; Reh C; Michaelis K; Rosillon D; Deroubaix X; Deprez D
Clin Pharmacokinet; 2005; 44(9):977-88. PubMed ID: 16122284
[TBL] [Abstract][Full Text] [Related]
6. Liver disease selectively modulates cytochrome P450--mediated metabolism.
Frye RF; Zgheib NK; Matzke GR; Chaves-Gnecco D; Rabinovitz M; Shaikh OS; Branch RA
Clin Pharmacol Ther; 2006 Sep; 80(3):235-45. PubMed ID: 16952490
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of carteolol by cDNA-expressed human cytochrome P450.
Kudo S; Uchida M; Odomi M
Eur J Clin Pharmacol; 1997; 52(6):479-85. PubMed ID: 9342584
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes.
Bellec G; Dréano Y; Lozach P; Ménez JF; Berthou F
Carcinogenesis; 1996 Sep; 17(9):2029-34. PubMed ID: 8824531
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
11. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
Rifkind AB; Lee C; Chang TK; Waxman DJ
Arch Biochem Biophys; 1995 Jul; 320(2):380-9. PubMed ID: 7625847
[TBL] [Abstract][Full Text] [Related]
12. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane.
Kharasch ED; Thummel KE
Anesthesiology; 1993 Oct; 79(4):795-807. PubMed ID: 8214760
[TBL] [Abstract][Full Text] [Related]
13. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.
Lieu C; Shi J; Donat F; Van Horn R; Brian W; Newton J; Delbressine L; Vos R
Clin Pharmacokinet; 2002; 41 Suppl 2():19-26. PubMed ID: 12383041
[TBL] [Abstract][Full Text] [Related]
14. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.
Coller JK; Somogyi AA; Bochner F
Br J Clin Pharmacol; 1999 Aug; 48(2):158-67. PubMed ID: 10417492
[TBL] [Abstract][Full Text] [Related]
15. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T
Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms.
Renwick AB; Mistry H; Ball SE; Walters DG; Kao J; Lake BG
Xenobiotica; 1998 Apr; 28(4):337-48. PubMed ID: 9604298
[TBL] [Abstract][Full Text] [Related]
17. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes.
Niwa T; Shiraga T; Hashimoto T; Kagayama A
Biol Pharm Bull; 2004 Mar; 27(3):415-7. PubMed ID: 14993813
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans.
Shimada T; Mimura M; Inoue K; Nakamura S; Oda H; Ohmori S; Yamazaki H
Arch Toxicol; 1997; 71(6):401-8. PubMed ID: 9195021
[TBL] [Abstract][Full Text] [Related]
19. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease.
Tanaka E; Breimer DD
J Clin Pharm Ther; 1997 Aug; 22(4):237-49. PubMed ID: 9548204
[TBL] [Abstract][Full Text] [Related]
20. Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes.
Niwa T; Shiraga T; Hashimoto T; Kagayama A
Biol Pharm Bull; 2004 Jan; 27(1):97-9. PubMed ID: 14709907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
